Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates

Journal of Perinatology

Volumn 25, Issue 11, 2005, Pages 709-713

  Sanjeev, Sanjeev ^a   Pettersen, Michael ^a   Lua, Jorge ^a   Thomas, Ronald ^a   Shankaran, Seetha ^a   L'Ecuyer, Thomas ^a  

^a Division of Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; INDOMETACIN;

ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; GESTATIONAL AGE; HEART SURGERY; HEMODYNAMICS; HUMAN; MALE; NEWBORN; NEWBORN SCREENING; PATENT DUCTUS ARTERIOSUS; PERINATAL PERIOD; PREMATURITY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; STATISTICAL MODEL;

DUCTUS ARTERIOSUS, PATENT; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 27844496718     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211383     Document Type: Article

References (27)

1. Reller MD, Lorenz JM, Kotagal UR, Meyer RA, Kaplan S. Hemodynamically significant PDA: An echocardiographic and clinical assessment of incidence, natural history, and outcome in very low birth weight infants maintained in negative fluid balance. Pediatr Cardiol 1985;6(1):17-23.
2. Shimada S, Kasai T, Hoshi A, Murata A, Chida S. Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. Pediatr Int 2003;45(3):255-62.
3. Evans N, Kluckow M. Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed 1996;75(3):F183-6.
4. Dudell GG, Gersony WM. Patent ductus arteriosus in neonates with severe respiratory disease. J Pediatr 1984;104(6):915-20.
5. Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: A systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2003;88(6):F464-6.
6. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001;344(26):1966-72.
7. Mellander M, Larsson LE, Ekstrom-Jodal B, Sabel KG. Prediction of symptomatic patent ductus arteriosus in preterm infants using Doppler and M-mode echocardiography. Acta Paediatr Scand 1987;76(4):553-9
8. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994;30(5):406-11.
9. Davis P, Turner-Gomes S, Cunningham K, Way C, Roberts R, Schmidt B. Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Arch Pediatr Adolesc Med 1995;149(10):1136-41.
10. Archer LN, Glass EJ, Godman MJ. The silent ductus arteriosus in idiopathic respiratory distress syndrome. Acta Paediatr Scand 1984;73(5):652-6.
11. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135(5 Part 1):825-32.
12. Maisel AS. B-type natriuretic peptide (BNP) levels: Diagnostic and therapeutic potential. Rev Cardiovasc Med 2001;2(Suppl 2):S13-8.
13. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107(22):2786-92.
14. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347(3):161-7.
15. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39(2):202-9.
16. Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka K, Kageyama M, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003;57(4):191-7.
17. Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002;103(1):75-7.
18. Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001;90(2):184-91.
19. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31(1):202-8.
20. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41(3):571-9.
21. Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol 2001;6(1):49-61.
22. Fleiss JL. Constant chi-square boundaries. In: Fleiss JL, editor. Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley & sons; 1981.
23. Muta H, Ishii M, Maeno Y, Akagi T, Kato H. Quantitative evaluation of the changes in plasma concentrations of cardiac natriuretic peptide before and after transcatheter closure of atrial septal defect. Acta Paediatr 2002;91(6):649-52.
24. Fagan TJ. Letter. Nomogram for Bayes theorem. N Engl J Med 1975;293(5):257.
25. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339(5):321-8.
26. Tsuchida K, Tanabe K. Influence of paroxysmal atrial fibrillation attack on brain natriuretic peptide secretion. J Cardiol 2004;44(1):1-11.
27. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 2004; 109(8):984-9.